Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma

ConclusionsThese results suggest that adenosinergic pathway might represent an applicable target for sorafenib-combined-therapies in human HCC.
Source: Hepatology International - Category: Infectious Diseases Source Type: research